World Pharma News Digest - 19.03.2012
1 view
Skip to first unread message
Ruslan David
Mar 19, 2012, 5:35:21 AM3/19/12
to worldph...@googlegroups.com
Want to place your News, Brand, Service, Product or Event in front of World Pharma News?
World Pharma News' strong, innovative capabilities can ensure you to create a compelling advertising campaign that reaches all your objectives and desired audiences. For further information, please download World Pharma News' Media Pack (.pdf, 319 KB).
Read more...
http://www.worldpharmanews.com/contact-us
World Pharma News' strong, innovative capabilities can ensure you to create a compelling advertising campaign that reaches all your objectives and desired audiences. For further information, please download World Pharma News' Media Pack (.pdf, 319 KB).
Read more...
http://www.worldpharmanews.com/contact-us
Sanofi to Acquire Pluromed, Inc., Expanding its Presence in Biosurgery
Sanofi (EURONEXT: SAN and NYSE: SNY) and Pluromed Inc. have entered into a definitive agreement under which Sanofi is to acquire Pluromed Inc., a medical device company based in Woburn, Massachusetts. The acquisition is subject to customary closing conditions.
Read more...
http://www.worldpharmanews.com/sanofi/2008-sanofi-to-acquire-pluromed-inc-expanding-its-presence-in-biosurgery
Sanofi (EURONEXT: SAN and NYSE: SNY) and Pluromed Inc. have entered into a definitive agreement under which Sanofi is to acquire Pluromed Inc., a medical device company based in Woburn, Massachusetts. The acquisition is subject to customary closing conditions.
Read more...
http://www.worldpharmanews.com/sanofi/2008-sanofi-to-acquire-pluromed-inc-expanding-its-presence-in-biosurgery
GlaxoSmithKline provides further update on divestment of non-core OTC brands
In February 2011, GSK announced its intention to divest non-core Consumer Healthcare over-the-counter (OTC) products predominantly in the United States and Europe with aggregate sales of approximately £500 million.
Read more...
http://www.worldpharmanews.com/gsk/2007-glaxosmithkline-provides-further-update-on-divestment-of-non-core-otc-brands
In February 2011, GSK announced its intention to divest non-core Consumer Healthcare over-the-counter (OTC) products predominantly in the United States and Europe with aggregate sales of approximately £500 million.
Read more...
http://www.worldpharmanews.com/gsk/2007-glaxosmithkline-provides-further-update-on-divestment-of-non-core-otc-brands
Cancer cells send out the alarm on tumor-killing virus
Brain-tumor cells that are infected with a cancer-killing virus release a protein "alarm bell" that warns other tumor cells of the impending infection and enables them to mount a defense against the virus, according to a study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James).
Read more...
http://www.worldpharmanews.com/research/2006-cancer-cells-send-out-the-alarm-on-tumor-killing-virus
Brain-tumor cells that are infected with a cancer-killing virus release a protein "alarm bell" that warns other tumor cells of the impending infection and enables them to mount a defense against the virus, according to a study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James).
Read more...
http://www.worldpharmanews.com/research/2006-cancer-cells-send-out-the-alarm-on-tumor-killing-virus
Roche receives request for additional information from the Federal Trade Commission
Roche (SIX: RO, ROG; OTCQX: RHHBY) has received a request for additional information, often referred to as a "second request," from the Federal Trade Commission ("FTC") in connection with Roche's proposed acquisition of Illumina, Inc. (NASDAQ: ILMN)
Read more...
http://www.worldpharmanews.com/roche/2004-roche-receives-request-for-additional-information-from-the-federal-trade-commission
Roche (SIX: RO, ROG; OTCQX: RHHBY) has received a request for additional information, often referred to as a "second request," from the Federal Trade Commission ("FTC") in connection with Roche's proposed acquisition of Illumina, Inc. (NASDAQ: ILMN)
Read more...
http://www.worldpharmanews.com/roche/2004-roche-receives-request-for-additional-information-from-the-federal-trade-commission
Influenza 'histone mimic' suppresses antiviral response
A team of researchers led by scientists at The Rockefeller University has identified a novel mechanism by which influenza interferes with antiviral host response. The finding, reported in this week's issue of the journal Nature, shows that the immunosuppressive NS1 protein of the influenza A virus hijacks key regulators of antiviral gene function by mimicking a core component of gene regulating machinery.
Read more...
http://www.worldpharmanews.com/research/2005-influenza-histone-mimic-suppresses-antiviral-response
A team of researchers led by scientists at The Rockefeller University has identified a novel mechanism by which influenza interferes with antiviral host response. The finding, reported in this week's issue of the journal Nature, shows that the immunosuppressive NS1 protein of the influenza A virus hijacks key regulators of antiviral gene function by mimicking a core component of gene regulating machinery.
Read more...
http://www.worldpharmanews.com/research/2005-influenza-histone-mimic-suppresses-antiviral-response
AstraZeneca files lawsuit against the FDA
AstraZeneca filed a lawsuit against the US Food and Drug Administration (FDA) in the US District Court for the District of Columbia to overturn the FDA's denial on 7 March 2012 of Citizen Petitions filed by AstraZeneca with regard to SEROQUEL® (quetiapine fumarate) tablets and SEROQUEL XR® (quetiapine fumarate) extended release tablets.
Read more...
http://www.worldpharmanews.com/astrazeneca/2003-astrazeneca-files-lawsuit-against-the-fda
AstraZeneca filed a lawsuit against the US Food and Drug Administration (FDA) in the US District Court for the District of Columbia to overturn the FDA's denial on 7 March 2012 of Citizen Petitions filed by AstraZeneca with regard to SEROQUEL® (quetiapine fumarate) tablets and SEROQUEL XR® (quetiapine fumarate) extended release tablets.
Read more...
http://www.worldpharmanews.com/astrazeneca/2003-astrazeneca-files-lawsuit-against-the-fda
Pfizer's Prevnar 13® shown to be immunogenic in older children and adolescents
Pfizer Inc. (NYSE:PFE) announced that data from a Phase 3 study of Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) met all study endpoints, showing immunogenicity and establishing a safety profile in children and adolescents aged 5 through 17 years.
Read more...
http://www.worldpharmanews.com/pfizer/2002-pfizers-prevnar-13r-shown-to-be-immunogenic-in-older-children-and-adolescents
Pfizer Inc. (NYSE:PFE) announced that data from a Phase 3 study of Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) met all study endpoints, showing immunogenicity and establishing a safety profile in children and adolescents aged 5 through 17 years.
Read more...
http://www.worldpharmanews.com/pfizer/2002-pfizers-prevnar-13r-shown-to-be-immunogenic-in-older-children-and-adolescents
PharmaNews.eu / Latest News
Nanopills release drugs directly from the inside of cells
http://www.pharmanews.eu/research-and-development/1019-nanopills-release-drugs-directly-from-the-inside-of-cells
http://www.pharmanews.eu/research-and-development/1019-nanopills-release-drugs-directly-from-the-inside-of-cells
MI Health Forum to provide the healthcare system with innovative prescriptions
http://www.pharmanews.eu/conferences-and-events/1018-mi-health-forum-to-provide-the-healthcare-system-with-innovative-prescriptions
http://www.pharmanews.eu/conferences-and-events/1018-mi-health-forum-to-provide-the-healthcare-system-with-innovative-prescriptions
IBM's biomedical analytics platform helps doctors personalize treatment
http://www.pharmanews.eu/research-and-development/1017-ibms-biomedical-analytics-platform-helps-doctors-personalize-treatment
http://www.pharmanews.eu/research-and-development/1017-ibms-biomedical-analytics-platform-helps-doctors-personalize-treatment
Paper calls for continued support for development of advanced therapies
http://www.pharmanews.eu/ema/1016-paper-calls-for-continued-support-for-development-of-advanced-therapies
http://www.pharmanews.eu/ema/1016-paper-calls-for-continued-support-for-development-of-advanced-therapies
European Medicines Agency launches electronic application form pilot
http://www.pharmanews.eu/ema/1015-european-medicines-agency-launches-electronic-application-form-pilot
http://www.pharmanews.eu/ema/1015-european-medicines-agency-launches-electronic-application-form-pilot
GSK reinforces commitment to youth training
http://www.pharmanews.eu/gsk/1014-gsk-reinforces-commitment-to-youth-training
http://www.pharmanews.eu/gsk/1014-gsk-reinforces-commitment-to-youth-training
Scientists map new mechanism in brain's barrier tissue
http://www.pharmanews.eu/research-and-development/1013-scientists-map-new-mechanism-in-brains-barrier-tissue
http://www.pharmanews.eu/research-and-development/1013-scientists-map-new-mechanism-in-brains-barrier-tissue
With best regards,
Ruslan David
Ruslan David
Administrator/Editor
PS: Download World Pharma News' Media Pack (.pdf, 214 KB) http://www.worldpharmanews.com/images/media_pack.pdf
Reply all
Reply to author
Forward
0 new messages